^
    Back
    Association details:
    Biomarker:PTEN underexpression
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:tamoxifen (Estrogen receptor antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Breast Cancer Res Treat
    Title:

    PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy

    Published date:
    01/03/2022
    Excerpt:
    Low PTEN expression and high methylation of its promoter (sequence − 819 to − 787 bp) in tissue predict poor DFS and OS in hormone receptor-positive early BC patients who received adjuvant TAM.
    DOI:
    10.1007/s10549-021-06463-6